{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:01:04Z","timestamp":1781820064052,"version":"3.54.5"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.canlet.2025.218131","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:46:53Z","timestamp":1762958813000},"page":"218131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Drug screening reveals differential drug response in primary and metastatic clear cell sarcoma"],"prefix":"10.1016","volume":"637","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-4399","authenticated-orcid":false,"given":"Djenana","family":"Vejzovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Karner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-2438","authenticated-orcid":false,"given":"Karoline","family":"Fechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Barones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-5911","authenticated-orcid":false,"given":"Nina A.","family":"Schweintzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3883-9990","authenticated-orcid":false,"given":"Freya","family":"Lyssy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gauster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Szkandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5858-4067","authenticated-orcid":false,"given":"Stefanie","family":"Stanzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Prietl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-6856","authenticated-orcid":false,"given":"Amin","family":"El-Heliebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-7902","authenticated-orcid":false,"given":"Birgit","family":"Lohberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3412-6051","authenticated-orcid":false,"given":"Maria Jose","family":"Guill\u00e9n-Navaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo M.","family":"Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9847-0171","authenticated-orcid":false,"given":"Iva","family":"Br\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Liegl-Atzwanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-4905","authenticated-orcid":false,"given":"Beate","family":"Rinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.canlet.2025.218131_bib1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc1168","article-title":"Mechanisms of sarcoma development","volume":"3","author":"Helman","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cncr.25538","article-title":"Trends in survival for patients with metastatic soft-tissue sarcoma","volume":"117","author":"Italiano","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.canlet.2025.218131_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrc3087","article-title":"Advances in sarcoma genomics and new therapeutic targets","volume":"11","author":"Taylor","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.218131_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ng0893-341","article-title":"EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts","volume":"4","author":"Zucman","year":"1993","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.canlet.2025.218131_bib5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","article-title":"The epigenomics of sarcoma","volume":"20","author":"Nacev","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.canlet.2025.218131_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/PAS.0b013e31814b18fb","article-title":"Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases","volume":"32","author":"Hisaoka","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.canlet.2025.218131_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2014.26","article-title":"Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies","volume":"11","author":"Linch","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218131_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100522","article-title":"Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network","volume":"7","author":"Smrke","year":"2022","journal-title":"ESMO Open"},{"issue":"13","key":"10.1016\/j.canlet.2025.218131_bib9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.218131_bib10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O'Dwyer","year":"2023","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.218131_bib11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","article-title":"Trametinib activity in patients with solid tumors and Lymphomas harboring BRAF Non-V600 mutations or fusions: results from NCI-MATCH (EAY131)","volume":"26","author":"Johnson","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.218131_bib13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav6528","article-title":"A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer","volume":"5","author":"Bangi","year":"2019","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib15","article-title":"Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial","volume":"4","author":"Ranjan","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.218131_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine Tumor Board for Acute Myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-022-03843-4","article-title":"Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines","volume":"21","author":"Karner","year":"2023","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.canlet.2025.218131_bib18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41588-018-0209-6","article-title":"Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy","volume":"50","author":"Lee","year":"2018","journal-title":"Nat. Genet."},{"issue":"W1","key":"10.1016\/j.canlet.2025.218131_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"19","key":"10.1016\/j.canlet.2025.218131_bib20","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.canlet.2025.218131_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giab008","article-title":"Twelve years of SAMtools and BCFtools","volume":"10","author":"Danecek","year":"2021","journal-title":"GigaScience"},{"issue":"7","key":"10.1016\/j.canlet.2025.218131_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.canlet.2025.218131_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"7","key":"10.1016\/j.canlet.2025.218131_bib25","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nmeth.3885","article-title":"Data-driven hypothesis weighting increases detection power in genome-scale multiple testing","volume":"13","author":"Ignatiadis","year":"2016","journal-title":"Nat. Methods"},{"issue":"18","key":"10.1016\/j.canlet.2025.218131_bib26","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib27","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci"},{"key":"10.1016\/j.canlet.2025.218131_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.placenta.2024.04.013","article-title":"The chicken chorioallantoic membrane assay revisited - a face-lifted approach for new perspectives in placenta research","volume":"166","author":"Lyssy","year":"2024","journal-title":"Placenta"},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.celrep.2012.12.013","article-title":"Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ","volume":"3","author":"Joo","year":"2013","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41467-024-55667-z","article-title":"Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity","volume":"16","author":"Cigrang","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2025.218131_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41419-020-2462-8","article-title":"Measurement and models accounting for cell death capture hidden variation in compound response","volume":"11","author":"Bae","year":"2020","journal-title":"Cell Death Dis."},{"issue":"19","key":"10.1016\/j.canlet.2025.218131_bib32","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","article-title":"Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer","volume":"18","author":"Vidal","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1476-5381.2010.00945.x","article-title":"PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity","volume":"161","author":"Leal","year":"2010","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41420-025-02566-x","article-title":"Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review","volume":"11","author":"Masuda","year":"2025","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.canlet.2025.218131_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2025.218131_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"El-Khoueiry","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10495","key":"10.1016\/j.canlet.2025.218131_bib38","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.canlet.2025.218131_bib39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/14796694.2025.2463798","article-title":"SaLudo: a randomized phase IIb\/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma","volume":"21","author":"Cote","year":"2025","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.218131_bib40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s10637-025-01583-y","article-title":"Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors","volume":"43","author":"Falc\u00f3n","year":"2025","journal-title":"Invest. N. Drugs"},{"issue":"6","key":"10.1016\/j.canlet.2025.218131_bib41","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","article-title":"Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor","volume":"26","author":"Christensen","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.canlet.2025.218131_bib42","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the Formation of DNA breaks in cancer cells","volume":"15","author":"Santamar\u00eda","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"18","key":"10.1016\/j.canlet.2025.218131_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26189085","article-title":"The DNA minor groove binders trabectedin and lurbinectedin are potent antitumor agents in human intrahepatic cholangiocarcinoma","volume":"26","author":"G\u00e4bele","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.canlet.2025.218131_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26188866","article-title":"Therapeutic effects of lurbinectedin in PARP inhibitor-resistant high-grade serous ovarian cancer using patient-derived cell lines and organoid models","volume":"26","author":"Srivastava","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.canlet.2025.218131_bib46","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-24-2556","article-title":"Synergistic effects of ATR inhibition and lurbinectedin in soft-tissue sarcomas: the predictive role of SLFN11 expression","volume":"31","author":"Laroche-Clary","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.canlet.2025.218131_bib47","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/0008-5472.CAN-16-0568","article-title":"Lurbinectedin inactivates the ewing Sarcoma Oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2025.218131_bib48","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1535-7163.MCT-21-1003","article-title":"Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor","volume":"21","author":"Gedminas","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"13","key":"10.1016\/j.canlet.2025.218131_bib49","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1158\/1078-0432.CCR-22-0696","article-title":"Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed ewing sarcoma: results of a basket phase II Study","volume":"28","author":"Subbiah","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218131_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2019.10.021","article-title":"A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and\/or unresectable sarcomas","volume":"126","author":"Cote","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218131_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1042479","article-title":"Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: a proof of principle from a post-hoc analysis","volume":"12","author":"Palmerini","year":"2022","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.canlet.2025.218131_bib52","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1016\/j.ejca.2012.05.012","article-title":"A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas","volume":"48","author":"Le Cesne","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib53","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1159\/000534935","article-title":"A clear cell sarcoma case: a diagnostic and treatment challenge, with a promising response to trabectedin","volume":"16","author":"Galera","year":"2023","journal-title":"Case Rep. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2025.218131_bib55","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218131_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186035","article-title":"LIN28B-mediated PI3K\/AKT pathway activation promotes metastasis in colorectal cancer models","volume":"135","author":"Shin","year":"2025","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.canlet.2025.218131_bib57","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","article-title":"Emerging connectivity of programmed cell death pathways and its physiological implications","volume":"21","author":"Bedoui","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","article-title":"Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity","volume":"24","author":"Meier","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.canlet.2025.218131_bib59","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1093\/annonc\/mdx527","article-title":"Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'","volume":"28","author":"Sch\u00f6ffski","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib60","first-page":"128","article-title":"Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis","volume":"4","author":"Garcia-Recio","year":"2023","journal-title":"Nat. Cancer"},{"issue":"7781","key":"10.1016\/j.canlet.2025.218131_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib62","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat. Genet."},{"issue":"8047","key":"10.1016\/j.canlet.2025.218131_bib63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41586-024-08150-0","article-title":"Progressive plasticity during colorectal cancer metastasis","volume":"637","author":"Moorman","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/0008-5472.CAN-24-1211","article-title":"Distant metastases of breast cancer resemble primary tumors in cancer cell composition but differ in immune cell phenotypes","volume":"85","author":"Kuett","year":"2025","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2025.218131_bib65","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","article-title":"Cancer cell plasticity during tumor progression, metastasis and response to therapy","volume":"4","author":"P\u00e9rez-Gonz\u00e1lez","year":"2023","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.218131_bib66","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.canlet.2025.218131_bib67","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.218131_bib68","article-title":"Cancer-associated fibroblast-derived GAS6 increases resistance to chemotherapy through AXL\/STAT3\/ABCG1 in gastric cancer","author":"Kim","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.218131_bib69","doi-asserted-by":"crossref","first-page":"9387","DOI":"10.1038\/s41467-025-64447-2","article-title":"FAP(+) fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus","volume":"16","author":"Ma","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2025.218131_bib70","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43018-024-00743-y","article-title":"Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy","volume":"5","author":"Subramanian","year":"2024","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2025.218131_bib71","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10262","key":"10.1016\/j.canlet.2025.218131_bib72","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:28:28Z","timestamp":1773808108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":72,"alternative-id":["S0304383525007037"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218131","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug screening reveals differential drug response in primary and metastatic clear cell sarcoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218131"}}